Morten Busch’s Post

According to early clinical data, a new experimental blood test can detect stage 1 and 2 pancreatic cancer with 97% accuracy. Although pancreatic cancer accounts for just 3% of new cancer diagnoses, it's one of the most fatal due to the difficulty of detecting it at an early stage. A quicker and earlier diagnosis means it's much more likely the cancer can be surgically removed before it spreads to other parts of the body, significantly increasing the likelihood of a full recovery. The clinical trial included patients from the US and Asia and will now be studied on a larger scale. #liquidbiopsy #IVD #cancerdiagnostics

Gathering Around Cancer Conference: Changing paradigms in first-line lung cancer @AdamJSchoenfeld #lungcancer #celltherapy #GatheringAroundCancer https://lnkd.in/eNYEJ8VM

Gathering Around Cancer Conference: Changing paradigms in first-line lung cancer @AdamJSchoenfeld #lungcancer #celltherapy #GatheringAroundCancer https://lnkd.in/eNYEJ8VM

➡️ This morning, a post that looks at some findings in #lungcancer, which in most countries, claims more lives each year than breast, colon, and prostate cancer combined. 🙏 Not the most uplifting topic but important research to hopefully, drive better treatements and #patient outcomes in the coming years and decades. 🤔 We should also be mindful not to stigmatize people with lung cancer as it has several causes. #cancer #stigma #sciencematters #researchmatters

Exciting advances are finally being made in the battle against small cell lung cancer (SCLC), as reported by MD Anderson Cancer Center. Dr. Carl Gay and his team have identified four subtypes of SCLC, paving the way for more personalized and effective treatments. Using blood-based assays to rapidly classify these subtypes means faster, more tailored therapies, moving us away from the one-size-fits-all approach. "We have a lot of new options that I think are going to be game changers in treating small cell lung cancer," said Dr. Gay. #lungcancer #sclc #medicalinnovation https://lnkd.in/g8Q-Dz46

The classification of small cell lung cancer (SCLC) into distinct subtypes represents a groundbreaking leap toward personalised medicine for a historically challenging cancer type. By leveraging innovations like blood-based assays and methylation pattern analysis, researchers are accelerating diagnosis and tailoring treatments—offering renewed hope for improved outcomes. Subtype-specific therapies, especially immune checkpoint inhibitors for SCLC-I, underscore the potential to transform SCLC care with precision approaches. #LungCancerAwareness #PersonalisedMedicine #SmallCellLungCancer

In honor of World Lung Cancer Day 2024, discover the latest advancements in lung cancer treatment, new FDA-approved therapies and promising clinical trials. Read more in our latest blog: https://buff.ly/3SvZYRH #WorldLungCancerDay #LungCancerAwareness #WorldLungCancerDay2024 #SmallCellLungCancer #NonSmallCellLungCancer

Summary of our paper on combining JAK inhibitors with anti-PD1 for lung cancer - Andy Minn E. John Wherry Divij Mathew Melina Marmarelis Joshua Bauml #Cancer #LCSM #NSCLC #CancerResearch #OncoDaily #Oncology

Cambridge scientists have developed a urine test for early detection of lung cancer. The test, the first of its kind, detects ‘zombie’ cells that could indicate the first signs of the disease. https://lnkd.in/dHgCuWHJ

The post sheds light on the crucial role of exosomes and microRNAs in the early detection of pancreatic cancer. Through the analysis of both free-floating and exosome-packaged microRNAs, significant advancements have been made in identifying this complex disease. A study involving over 100 individuals with pancreatic cancer showcased the test's exceptional accuracy in detecting both early and late stages of the illness. This milestone underscores the potential of exosomes and microRNAs as valuable tools for the prompt diagnosis of pancreatic cancer. Dive deeper into this groundbreaking research by visiting the provided link. #PancreaticCancer #EarlyDetection Link to the post: https://lnkd.in/e96whAzr